Taiwan and the UK sign an MOU on the deposit of biological materials for the purposes of patent procedureOn November 29, 2017, Director General Hong Shu-min of the Taiwan Intellectual Property Office (TIPO) embarked on a visit to the UK. During her visit, she signed an MOU on the deposit of biological materials for the purposes of patent procedure with Chief Executive Officer Tim Moss of the Intellectual Property Office of the UK. TIPO has always attached great importance to facilitating cooperation on the deposit of biological materials with other countries, which is in line with one of Taiwan’s major policies to promote the biotechnology and pharmaceutical industries. As most patent applications filed to TIPO by UK nationals or companies are in the fields of biotechnology, medicine, and pharmaceuticals, and as the number of application has been on the increase in recent years, TIPO approached the UK IPO on its initiative to explore the possibility of working together on this front. After years of hard work, the two offices finally signed in London on December 1, 2017, the MOU, which has come into effect immediately. This is yet another milestone for TIPO, further expanding its cooperation with other IP authorities, after it facilitated the signing of a similar MOU between Taiwan and Japan in 2015. On December 1, 2017, TIPO and the UK IPO also held a heads meeting to exchange views on issues of mutual concern, including measures to combat online copyright infringement and to improve the quality of patent examination, Taiwan’s online patent application system, and the post-Brexit impact on IP matters. The two sides both agreed to continue their dialogue and have discussions on issues such as IP support for SMEs through desktop video conferences in the future.